Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Targeting Oncogenic WNT Signalling with WNT Signalling-Derived Peptides

Yadav, Vikas LU ; Jobe, Njainday LU ; Mehdawi, Lubna LU and Andersson, Tommy LU (2021) In Handbook of experimental pharmacology p.279-303
Abstract
WNT signalling is known to be a crucial regulator of embryonic development and tissue homeostasis. Aberrant expression of WNT signalling elements or their mutations has been implicated in carcinogenesis and/or the progression of several different cancer types. Investigations of how WNT signalling affects carcinogenesis and cancer progression have revealed that it has essential roles in the regulation of proliferation, apoptosis, and cancer stemness and in angiogenesis and metastasis. Consequently, WNT-targeted therapy has gained much attention and has resulted in the development of several small molecules, the majority of which act as inhibitors of different WNT signalling events. However, although numerous inhibitory WNT signalling drug... (More)
WNT signalling is known to be a crucial regulator of embryonic development and tissue homeostasis. Aberrant expression of WNT signalling elements or their mutations has been implicated in carcinogenesis and/or the progression of several different cancer types. Investigations of how WNT signalling affects carcinogenesis and cancer progression have revealed that it has essential roles in the regulation of proliferation, apoptosis, and cancer stemness and in angiogenesis and metastasis. Consequently, WNT-targeted therapy has gained much attention and has resulted in the development of several small molecules, the majority of which act as inhibitors of different WNT signalling events. However, although numerous inhibitory WNT signalling drug candidates have been included in clinical trials, no significant breakthroughs have been made. This could possibly be due to problems with inefficient binding to the target, compensatory signalling mechanisms and toxicity towards normal cells. Therapeutic peptides targeting WNT signalling in cancer cells have been developed as an alternative approach, with the hope that they might overcome the limitations reported for small WNT inhibitory molecules. In this chapter, we describe recent developments made in the design and characterization of WNT signalling-derived peptides aiming at their use as alternative cancer therapeutics and/or combined adjuvant therapy to conventional therapies. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Chapter in Book/Report/Conference proceeding
publication status
published
subject
host publication
Handbook of experimental pharmacology
series title
Handbook of experimental pharmacology
pages
279 - 303
publisher
Springer
external identifiers
  • scopus:85118528680
  • pmid:34455485
ISSN
0171-2004
ISBN
978-3-030-85499-7
978-3-030-85498-0
DOI
10.1007/164_2021_528
language
English
LU publication?
yes
id
a3a86c41-2456-46ab-b6f6-6b359fcf67ad
alternative location
https://link.springer.com/chapter/10.1007/164_2021_528
date added to LUP
2021-08-30 14:50:00
date last changed
2025-03-09 16:54:49
@inbook{a3a86c41-2456-46ab-b6f6-6b359fcf67ad,
  abstract     = {{WNT signalling is known to be a crucial regulator of embryonic development and tissue homeostasis. Aberrant expression of WNT signalling elements or their mutations has been implicated in carcinogenesis and/or the progression of several different cancer types. Investigations of how WNT signalling affects carcinogenesis and cancer progression have revealed that it has essential roles in the regulation of proliferation, apoptosis, and cancer stemness and in angiogenesis and metastasis. Consequently, WNT-targeted therapy has gained much attention and has resulted in the development of several small molecules, the majority of which act as inhibitors of different WNT signalling events. However, although numerous inhibitory WNT signalling drug candidates have been included in clinical trials, no significant breakthroughs have been made. This could possibly be due to problems with inefficient binding to the target, compensatory signalling mechanisms and toxicity towards normal cells. Therapeutic peptides targeting WNT signalling in cancer cells have been developed as an alternative approach, with the hope that they might overcome the limitations reported for small WNT inhibitory molecules. In this chapter, we describe recent developments made in the design and characterization of WNT signalling-derived peptides aiming at their use as alternative cancer therapeutics and/or combined adjuvant therapy to conventional therapies.}},
  author       = {{Yadav, Vikas and Jobe, Njainday and Mehdawi, Lubna and Andersson, Tommy}},
  booktitle    = {{Handbook of experimental pharmacology}},
  isbn         = {{978-3-030-85499-7}},
  issn         = {{0171-2004}},
  language     = {{eng}},
  month        = {{08}},
  pages        = {{279--303}},
  publisher    = {{Springer}},
  series       = {{Handbook of experimental pharmacology}},
  title        = {{Targeting Oncogenic WNT Signalling with WNT Signalling-Derived Peptides}},
  url          = {{http://dx.doi.org/10.1007/164_2021_528}},
  doi          = {{10.1007/164_2021_528}},
  year         = {{2021}},
}